In:
Sexually Transmitted Diseases, 1991, Vol.18(1), pp.36-40
Description:
In developed nations, the most common sexually transmitted disease is infection with Chlamydia trachomatis. In the United States, the standard therapy for chlamydia infections involves a seven-day treatment period with tetracycline, erythromycin, or doxycycline. However, some cases require a longer treatment period, up to 21 days, to eliminate the infection. After the treatment period has ended, the patient is retested to make sure that the infection has been cured. This procedure is called a test-of-cure (TOC). But recurrent infections with the same strain of Chlamydia trachomatis, following seven days of treatment and TOC, are not uncommon, and may indicate that the standard therapy time should be increased. In an attempt to evaluate the relationship between the duration of treatment and the rate of recurrence of infection, the medical records of 2,983 patients, who were treated with the standard therapy for chlamydia infection, were reviewed. During a two-year follow-up period, the rate of recurrence of infection was 29 percent. Recurrence of infection was associated with young age, but not with gender or race. To determine if a longer treatment period could reduce the rate of recurrence of infection, 220 patients with chlamydia were treated with tetracycline for either 7 or 21 days. Among patients who returned, the recurrence rate was 14 percent for the seven-day treatment and 18 percent for the 21-day treatment. The difference in the recurrence rate between the two treatment groups was not statistically significant. It is concluded that a 21-day treatment period is no more effective than a seven-day treatment period in preventing recurrence of chlamydia infection. (Consumer Summary produced by Reliance Medical Information, Inc.)
Keywords:
Tetracyclines -- Evaluation ; Chlamydia Infections -- Drug Therapy ; Chlamydia Trachomatis;
ISSN:
0148-5717
E-ISSN:
15374521
DOI:
10.1097/00007435-199101000-00008
URL:
View record at Wolters Kluwer Health Ovid Technologies
Bookmarklink